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Abstract: The derangement of the cardiac energy substrate metabolism plays a key role in the pathogenesis of heart failure. The utiliza-
tion of non-carbohydrate substrates, such as fatty acids, is the predominant metabolic pathway in the normal heart, because this provides 
the highest energy yield per molecule of substrate metabolized. In contrast, glucose becomes an important preferential substrate for me-
tabolism and ATP generation under specific pathological conditions, because it can provide greater efficiency in producing high energy 
products per oxygen consumed compared to fatty acids. Manipulations that shift energy substrate utilization away from fatty acids toward 
glucose can improve the cardiac function and slow the progression of heart failure. However, insulin resistance, which is highly prevalent 
in the heart failure population, impedes this adaptive metabolic shift. Therefore, the acceleration of the glucose metabolism, along with 
the restoration of insulin sensitivity, would be the ideal metabolic therapy for heart failure. This review discusses the therapeutic potential 
of modifying substrate utilization to optimize cardiac metabolism in heart failure.  
Keywords: myocardial glucose and fatty acid metabolism, insulin resistance, metabolic therapy, heart failure. 
INTRODUCTION 
  Heart failure is currently a leading cause of death and disability 
across the globe. Although significant advances in the pharmacol-
ogical and mechanical (resynchronization therapy, left ventricular 
assisted devices) treatments have improved the outcome of patients 
with heart failure, the prognosis of such patients still remains poor. 
At present, the optimal pharmacological treatment of heart failure 
targets the suppression of neurohumral activation (such as the 
renin-angiotensin-aldosterone system (RAAS) and/or  -adrenergic 
receptor signaling), as well as regulating the fluid volume overload 
and hemodynamics, and optimizing heart rate. Novel therapeutic 
strategies acting independently from the neurohumoral axis are 
required to improve the patient outcomes. Emerging evidence sup-
ports the concept that disturbances in myocardial energy substrate 
metabolism contribute to the progression of cardiac contractile 
dysfunction and ventricular remodeling in patients with heart fail-
ure [1].  
  There is ample evidence to suggest that patients with heart fail-
ure have a reduced ability to generate ATP by myocardial oxidative 
metabolism. Therefore, the optimization of cardiac energy metabo-
lism, without any direct negative hemodynamic effects, is a concep-
tually attractive therapeutic approach. In this review, we will first 
outline the normal cardiac energy metabolism, and then focus on 
the metabolic derangements that occur during heart failure. Finally, 
we discuss the potential therapeutic applications of optimizing en-
ergy metabolism for treating heart failure.  
MYOCARDIAL SUBSTRATE METABOLISM IN THE 
NORMAL HEART 
  Before the dysfunctional myocardial energy metabolism in 
heart failure can be fully appreciated, it is important to have a thor-
ough understanding of the regulation of physiological energy me-
tabolism in the normal heart (Fig. (1)).  
The first step: Metabolism
  The utilization of free fatty acids (FFAs) and glucose in the 
mitochondria accounts for the vast majority of ATP production in  
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the healthy adult heart [2]. Under normal circumstances at rest, 60-
90% of the acetyl-CoA which enters the tricarboxylic acid (TCA) 
cycle comes from the  -oxidation of FFAs, and 10-40% from the 
oxidation of pyruvate that is derived in almost equal amounts from 
glycolysis and lactate oxidation [1-4]. However, during conditions 
of increased metabolic demands, such as increased heart rate or 
blood pressure, a shift towards a greater utilization of glucose is 
observed. 
Glucose (Carbohydrate) Metabolism 
  Glucose transport into cardiomyocytes occurs along a steep 
concentration gradient and is regulated by the specific transmem-
brane glucose transporters (GLUTs) in the sarcolemma. Intracellu-
lar glucose is phosphorylated to glucose-6-phosphate (G-6-P) by 
hexokinase, which is then utilized for the glycolytic pathway for 
energy production and/or glycogen synthesis. Phosphofructokinase 
(PFK)-1 catalyzes the phosphorylation of fructose-6-phosphate into 
fructose-1,6-bisphosphate. AMP and fructose 2,6-bisphosphate are 
positive effectors for this first irreversible step, whereas ATP, cit-
rate, and protons are negative allosteric effectors. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) catalyzes the conversion of 
glyceraldehyde 3-phosphate to 1,3-diphosphoglycerate [5], which is 
ultimately broken down to pyruvate. Pyruvate dehydrogenase 
(PDH), localized within the inner mitochondrial membrane, cata-
lyzes pyruvate decarboxylation and transformation into acetyl-CoA, 
which is subsequently fed into the TCA cycle. PDH is inactivated 
by a specific PDH kinase and is activated by a specific PDH phos-
phatase. The expression of PDH kinase is increased by starvation, 
diabetes and peroxisome proliferator activated receptor (PPAR)-
ligands, and the kinase is activated by acetyl-CoA and NADH (pro-
duced mainly by fatty acid oxidation (FAO)), which also directly 
inhibit PDH. In contrast, PDH kinase is inhibited by pyruvate and 
by decreases in the acetyl-CoA/free CoA and NADH/NAD
+ ratios. 
The PDH phosphatase is mainly activated by increased mitochon-
drial Ca
2+ entry under such conditions as catecholamine stimula-
tion. 
Fatty Acid Metabolism 
  The rate of FFA uptake by the heart is determined by the con-
centration of nonesterified fatty acids (NEFAs) in the plasma. FFAs 
enter the cardiomyocytes by either passive diffusion or by protein-
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fatty acid translocase (FAT) and a plasma membrane fatty acid 
binding protein (FABP). Once transported across the sarcolemma, 
NEFAs bind to FABP, and are then activated by esterification to 
fatty acyl-CoA by fatty acyl-CoA synthetase (FACS). Long-chain 
fatty acids on fatty acyl-CoA are then transferred to carnitine by 
carnitine palmitoyltransferase (CPT)-I and the resultant long chain 
acylcarnitine transported into the mitochondria. The long chain 
fatty acids from acylcarnitine are then converted back to long chain 
acyl-CoA by CPT-II. CPT-I plays a key regulatory role in control-
ling the rate of FFAs uptake by the mitochondria. Malonyl-CoA, 
which is a potent inhibitor of CPT-I, is produced by acetyl-CoA 
carboxylase (ACC) and is degraded by malonyl-CoA decarboxylase 
(MCD). Once in the mitochondria, long chain acyl-CoA undergoes 
-oxidation, which releases acetyl-CoA for the TCA cycle, and also 
regenerates acyl-CoA of two carbons shorter for another round of 
-oxidation. The principal products of fatty acid ß-oxidation (FAO) 
are NADH, FADH2, and acetyl-CoA, which generates more NADH 
and FADH2 in the TCA cycle.  
Interaction of Fatty Acid and Glucose Metabolism 
  FAO is the primary physiological regulator of glucose oxidation 
in the heart. High rates of FAO inhibit PDH by PDH kinase activa-
tion through an increase in the acetyl-CoA/free CoA and 
NADH/NAD
+ ratios (Fig. (1)). Conversely, inhibition of FAO in-
creases glycolysis and glucose oxidation both by decreasing citrate 
levels (which releases inhibition of PFK), and by lowering the ace-
tyl-CoA and/or NADH levels in the mitochondrial matrix, thereby 
relieving the inhibition of PDH. On the other hand, glucose may 
also inhibit FAO. Conditions that increase the production of acetyl-
CoA from pyruvate stimulate the production of malonyl-CoA, 
thereby inhibiting CPT activity.  
The Second Step: Oxidation
  The catabolic pathways for carbohydrates (glucose and lactate), 
FFAs, and some amino acids all converge on the formation of ace-
tyl-CoA, which serves as the metabolic substrate of the TCA cycle. 
The TCA cycle has the dual purposes of completing the decarboxy-
lation of acetyl-CoA and of producing NADH and FADH2 used in 
the electron transport chain to provide the energy for ATP synthe-
sis. The flux of the TCA cycle is tightly coupled to the capacity for 
ATP generation, which depends on the availability of oxygen, the 
cytosolic ATP/ADP+Pi ratio, and the NADH/ NAD
+ ratio in the 
mitochondria. An elevated ATP/ADP ratio under the conditions of 
low myocardial demand for ATP or the non-availability of oxidized 
cofactors (NAD
+ or FAD) is a powerful inhibitor of this cycle.  
  The NADH and FADH2 derived from glycolysis, FAO, and the 
TCA cycle are shuttled through the electron transport chain for 
oxidative phosphorylation. ATP is generated through the sequence 
of electron transfer to oxygen.  
The third Step: ATP Transfer and Utilization
  The ATP transfer and utilization for contraction is the final step 
of the myocardial energetic metabolic loop. The reaction can be 
expressed as follows:  
Phosphocreatine (PCr) + ADP         Creatine  (Cr)  +  ATP  
                                            (catalyzed by CK) 
Fig. (1). Normal myocardial energy metabolism.  
ANT, adenine nucleotide translocase; ACC, acetyl-CoA carboxylase; CPT, carnitine palmitoyltransferase; FABP, fatty acid binding protein; FACS, fatty acyl-
CoA synthase; FAT, fatty acid transporter; FFA, free fatty acid; GLUT, glucose transporter; G-6-P, glucose-6-phosphate; MCD, malonyl-CoA decarboxylase; 
PFK, Phosphofructokinase; PDH, pyruvate dehydrogenase; TCA, tricarboxylic acid cycle. 
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  This reaction can generate ATP ten times faster than that which 
occurs via oxidative phosphorylation. PCr is a vital energy buffer 
molecule that provides phosphoryl groups to ADP to rapidly gener-
ate ATP. The PCr/ATP ratio is a measure of myocardial energetics, 
and its reduction may depend on an imbalance of the myocardial 
oxygen supply and demand. Interestingly, this ratio is reduced in 
human heart failure [6], thus indicating that this ratio is a significant 
predictor of mortality [7].  
  The heart has a high energy demand, due to the need for ATP 
for muscle contraction, and for the maintenance of ATP-dependent 
cellular processes, including ion transport and intracellular Ca
2+
homeostasis. Approximately 60-70% of ATP hydrolysis fuels con-
tractile shortening, and the remaining 30-40% is primarily used for 
sarcoplasmic reticulum Ca
2+-ATPase (SERCA2A) and other ion 
pumps (Fig. (2)) [1].  
MYOCARDIAL SUBSTRATE METABOLISM IN HEART 
FAILURE 
Energy Production from Various Energy Substrates 
  Each of the myocardial substrates has a different ATP yield, 
calculated by the molar value or oxygen equivalents consumed per 
high energy phosphate produced. FFAs, such as palmitate, provides 
the highest energy (ATP) yield per molecule of substrate metabo-
lized, mainly through -oxidation [8]. However, while glucose pro-
vides less ATP yield per molecule, glucose metabolism has a 
greater efficiency in producing high energy phosphates (there is an 
up to a 40% increase in ATP production per oxygen molecule con-
sumed for glucose versus FFAs) [1, 4, 8, 9]. In other words, FAO 
requires a greater oxygen consumption for an equivalent amount of 
ATP synthesized compared to glucose oxidation (approximately 
15% more oxygen is required to produce the same amount of ATP 
from FAO [8, 10]). Moreover, increased FFAs levels, which are 
frequently associated with heart failure [11, 12], promote the syn-
thesis of uncoupling proteins, which leads to proton leakage, and 
subsequently, the dissipation of the electrochemical gradient across 
the inner mitochondrial membrane, resulting in the reduction of 
cardiac efficiency by limiting ATP production and increasing oxy-
gen consumption [13-15]. Therefore, glucose may become a favor-
able substrate for energy production in the heart during a state of 
increased energy metabolic demands, such as heart failure.  
Significance of Glycolytic ATP Production 
  Glycolysis contributes only approximately 5% of the total ATP 
generated in the normally oxygenated heart [10]. During ischemia, 
the mitochondrial metabolic dysfunction caused by reduced oxygen 
delivery to the heart results in a decrease in ATP formation by oxi-
dative phosphorylation [4]. The reduction in aerobic ATP formation 
accelerates glycolysis, glucose uptake and glycogen breakdown, 
leading to an increase in the contribution of glycolysis as a source 
of ATP production [2]. During moderate myocardial ischemia, the 
sustenance of glycolysis may be beneficial. Glycolytically gener-
ated ATP is responsible for the maintenance of ion homeostasis, 
particulary Na
+/K
+-ATPase and SERCA2A [16], and thus may be 
essential for optimal diastolic relaxation [17] (Fig. (2)). However, 
during anoxia or severe ischemia, when glucose oxidation cannot 
be increased in parallel with the accelerated glycolysis, the in-
creased glycolysis flux results in an accumulation of protons (H
+)
and lactate, which may be detrimental to the heart. Increased 
Na
+/H
+ exchanger activity for the efflux of the accumulated H
+
during ischemia-reperfusion increases the intracellular Na
+ concen-
tration, which activates the reverse mode of the Na
+/Ca
2+ exchanger 
and eventually leads to intracellular Ca
2+ overload [18, 19].  
Metabolic Substrate Changes in Heart Failure 
  Although there is quite a large body of work describing the role 
of myocardial energy substrate metabolism in the natural history of 
heart failure, we continue to have a poor understanding of the pre-
cise regulatory mechanisms that affect the expression of metabolic 
proteins. The normal adaptive response of the failing heart involves 
a complex series of enzymatic shifts and changes in the regulation 
of transcription factors, ultimately resulting in the switch in sub-
strate metabolism away from FAO toward greater glucose metabo-
lism to maximize efficiency [9, 20]. However, some studies have 
shown that there is not a decrease in FAO in the early stages of 
heart failure, and that a dramatic reduction of FAO enzymes, and 
Fig. (2). ATP regulates the electrolyte balance, including Ca
2+ homeostasis. 
CICR, Ca-induced Ca release; NCX, Na
+/Ca
2+ exchanger; NHE, Na
+/H
+ exchanger; SERCA, sarcoplasmic reticulum Ca
2+ ATPase pump. 
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consequently, the increase in glucose metabolism, occurs only in 
advanced or end-stage decompensated heart failure [21-23]. In fact, 
one study using positron emission tomography (PET) demonstrated 
increased myocardial FFA uptake and reduced glucose uptake in 
human heart failure [24]. The discrepancies among these clinical 
investigations may be attributed to the severity of heart failure in 
the subjects being studied. However, there are also other potential 
explanations for these results.  
  One ptoential mechanism is the presence of "Insulin Resis-
tance" which is highly prevalent in the heart failure population, and 
plays the pivotal role in the pathogenesis of heart failure [9, 25]. 
Studies in the canine rapid pacing heart failure model demonstrated 
a progressive increase in insulin resistance during disease progres-
sion [26]. Moreover, elevated plasma FFA levels, which are com-
monly present in heart failure, impair insulin signaling [27]. Fur-
thermore, the activation of the RAAS occurring in patients with 
heart failure increases myocardial insulin resistance. In fact, angio-
tensin II stimulation of cardiac myocytes leads to the inhibition of 
insulin receptor downstream signaling. Therefore, although glucose 
is the preferential substrate for metabolism in patients with heart 
failure (the metabolic shift from FAO to glucose metabolism), insu-
lin resistance inhibits this adaptive response, resulting in further 
deterioration of heart failure and a state of energy deficiency. 
Therefore, the ideal metabolic therapy for heart failure would be to 
induce glucose metabolism, together with the improvement of insu-
lin sensitivity, while simultaneously blocking FFA uptake and 
FAO.  
Alternate Considerations for Metabolic Substrate Changes in 
Heart Failure 
  There is little evidence of the upregulation of proteins involved 
in the carbohydrate utilization pathway, even though an increase in 
glucose metabolism occurs during end-stage heart failure. Further-
more, there is actually either no change (GLUT1 and 4) or down-
regulation (GAPDH and PDH) of key enzymes involved in carbo-
hydrate metabolism in failing hearts, despite an increase in glucose 
uptake and oxidation [22, 28]. Recently, a couple reports demon-
strated that myocardial lipid storage is reduced in heart failure [29, 
30]. Moreover, it has been suggested that glucose oxidation at the 
mitochondria increases via anaplerotic flux in heart failure, thereby 
compensating for reduced PDH activity and maintaining the TCA 
cycle flux [31, 32]. Together, these results suggest that any increase 
in glucose metabolism in heart failure is due to alterations in path-
way regulation that are secondary to the suppression of FAO and/or 
the upregulation of the anaplerotic pathway. However, these shifts 
indicate a less efficient mode of carbon use for fueling energy syn-
thesis in the myocardium [31]. Therefore, restoration of endoge-
nous fatty acid stores, oxidation and mitochondrial function may be 
potentially useful as an alternate therapeutic target for heart failure.  
Alterations in the Expression and Function of Metabolic Regu-
lators and Their Therapeutic Potential for Optimizing Energy 
Metabolism in Heart Failure 
AMPK 
  AMP-activated protein kinase (AMPK) is an important energy-
sensing/signaling system, which regulates FAO and glucose uptake 
in response to altered energy supply and/or demand [33]. This 
kinase is activated by an increased ratio of AMP to ATP and/or a 
decreased ratio of PCr to creatine, which then counteracts the in-
creased rates of ATP utilization and maximizes ATP production to 
meet the energy demands. AMPK stimulates glucose uptake by an 
increase in GLUT1 expression and GLUT4 translocation to the 
plasma membrane [34], and accelerates glycolysis by activating 
PFK-2. The acute activation of AMPK also enhances FAO through 
a phosphorylation and decrease in acetyl-CoA carboxylase (ACC) 
activity [33]. In contrast, chronic AMPK activation is associated   
with decreased expression of CPT-1 and medium chain acetyl-CoA 
dehydrogenase (MCAD), resulting in decreased FAO [34]. There-
fore, AMPK plays an important energy metabolic role through the 
insulin-independent activation of glucose uptake and glycolysis, 
with biphasic actions on FAO. Further confirming this role, there is 
a paper recently demonstrated that macrophage migration inhibitory 
factor (MIF), which is released in the ischemic heart, stimulates 
AMPK, and protects the heart against ischemic injury and apoptosis 
[35]. 
Insulin/IGF-1 Signaling 
  PI3K-Akt, the down-stream effectors of insulin/IGF-1 signal-
ing, are key regulators of cardiomyocyte growth and survival [36, 
37], and are also important modulators of metabolic substrate utili-
zation and cardiomyocyte function [38-40]. It is widely accepted 
that acute activation or, to be more precise, the acute acceleration 
(superinduction) of insulin/IGF-1-PI3K-Akt signaling has carido-
protective effects both in vitro and in vivo [38, 41-44]. In contrast, 
we and others have previously demonstrated that chronic activation 
of Akt leads to detrimental outcomes due to either negative feed-
back inhibition of its upstream molecules, such as insulin receptor 
substrate (IRS)-1 [45], or a disruption of coordinated hypertrophy 
and angiogenesis [46, 47]. From the viewpoint of the cardiac me-
tabolism, Akt activation generally promotes the intracellular trans-
port and metabolism of glucose, while it inhibits FFA metabolism 
[48, 49]. The acute activation of Akt appears to increase glucose 
uptake, predominantly through enhanced sarcolemmal GLUT4 
localization [38], while its chronic activation leads to insulin resis-
tance, with a substantial decrease in GLUT4 both in the intracellu-
lar cytosol and on the sarcolemal membrane, in addition to negative 
feedback inhibition of IRS-1-PI3K coupling [40, 45]. In human 
advanced heart failure, Akt is paradoxically activated, with the 
concomitant reduction of IRS-1 [45, 50], thus suggesting a mecha-
nism by which chronic Akt activation may become maladaptive, in 
contrast to its acute activation (Fig. (3)). In contrast, other groups 
have shown that Akt activity is not elevated in heart failure, or is 
actually decreased in advanced heart failure due to the disturbed 
signal transduction of the upstream effectors, including the insu-
lin/IGF-1 receptor, through the IRS-1-PI3K pathway [25, 51, 52]. 
This discrepancy could be related to the differences in the severity 
and chronicity of ventricular dysfunction between the studies. 
Taken together, superinduction of PI3K-Akt signaling appears to 
play a central role in cardioprotection both via modification of en-
ergy metabolism and via mechanism(s) independent of metabolism, 
such as the direct anti-apoptotic effects. Likewise, the activation of 
the insulin/IGF-1 cascade preserves mitochondrial energy metabo-
lism, which in turn counteracts cardiotoxic oxidative stress and 
promotes survival in heart failure [53].  
  In addition to its metabolic effects, the activation of IGF-1-
PI3K-Akt signaling upregulates SERCA2A activity, which leads to 
enhancement of sarcoplasmic reticulum Ca
2+ uptake [54-56]. 
Therefore, the activation of this cascade could represent another 
therapeutic strategy for the improvement of cardiac contractility in 
heart failure, although this effect is mostly due to chronic activation 
of Akt, and would need to be confirmed in additional experimental 
models.  
Pyruvate 
  Pyruvate increases the contractile function and potentiates the 
contractile effects of -adrenergic stimulation in both the normal 
and failing myocardium [57, 58]. Pyruvate can increase the intracel-
lular Ca
2+ transients as a result of increased sarcoplasmic reticulum 
Ca
2+ accumulation, as well as increased myofilament Ca
2+ sensitiv-
ity as a result of the increased intracellular pH. Similarly, PDH 
kinase inhibition activates PDH and increases pyruvate oxidation, 
thus resulting in an increase in mechanical efficiency by switching 
the heart towards a more efficient fuel.  3850 Current Pharmaceutical Design, 2011, Vol. 17, No. 35  Nagoshi et al. 
GLP-1 
  The elevation of the plasma insulin concentration enhances 
glucose metabolism and inhibits FAO. Glucagon-like peptide 
(GLP)-1 is one of the incretins which promotes post-prandial insu-
lin secretion and improves insulin sensitivity. GLP-1 infusion in-
creases glucose uptake and improves cardiac function in a pacing-
induced heart failure model [59], although in a human heart failure 
study, short-term GLP-1 treatment failed to show any beneficial 
effects [60]. Since GLP-1 is rapidly degraded by dipeptidyl pepti-
dase (DPP)-IV in vivo, synthetic GLP-1 analogues with an extended 
plasma half-life (e.g. liraglutide) and GLP-1 receptor agonists (e.g. 
exenatide) have been developed. A DPP-IV antagonist would pro-
vide an alternative promising agent in this context. Indeed, sita-
gliptin, one of the DPP-IV inhibitors, has been shown to improve 
left ventricular performance in response to dobutamine stress in 
patients with coronary artery disease in an insulin-independent 
manner [61]. However, at present, there is insufficient evidence to 
support and/or suggest the use of incretins in heart failure. 
FFA Metabolism Modulators 
  Increasing FFA metabolism leads to an increase in oxygen con-
sumption, and is less efficient source of energy compared to glu-
cose metabolism (with regard to ATP production/oxygen con-
sumed), as discussed above. Moreover, if myocardial FFA uptake 
overwhelms the oxidative capacity of the heart, FFAs can accumu-
late as intramyocardial lipids (triglycerides, diacylglycerol, long 
chain acyl CoA’s and ceramides), which are associated with "lipo-
toxicity", leading to further impairment of the cardiac function, in 
addition to insulin resistance [3, 27, 62, 63]. In fact, high circulating 
lipid levels and intracellular accumulation of long-chain fatty acid 
moieties, such as that which occurs during fasting or in patients 
with diabetes, enhance PPAR- mediated expression of PDH 
kinase, thus resulting in the inhibition of the phosphorylation of 
PDH. Therefore, pharmacological interventions aimed at lowering 
circulating FFA levels, inhibiting FFA cellular and/or mitochon-
drial uptake, and inhibiting fatty acid  -oxidation could provide 
another therapeutic strategy for optimizing cardiac metabolism.  
  Trimetazidine is a metabolic agent initially developed for the 
treatment of myocardial ischemia. Its effect is achieved by shifting 
the energy substrate preference from fatty acid oxidation to glucose 
oxidation, secondary to inhibition of 3-ketoacylCoA thiolase (3-
KAT), the final enzyme in  -oxidation [64]. In experimental stud-
ies, trimetazidine exerts a cardioprotective effect in in vitro models 
of myocardial ischemia through a rapid restoration of oxidative 
phosphorylation processes, protection of cardiac cells against the 
accumulation of protons, and prevention of the intracellular accu-
mulation of sodium and calcium ions. These effects of trimetazidine 
are believed to help maintain the integrity of cell membranes, as 
well as maintain mitochondrial structure and function. Because of 
the preferential promotion of glucose and pyruvate oxidation, 
trimetazidine improves the activity of two membrane-bound pumps, 
namely the Na
+/K
+-ATPase and SERCA2A, which are responsible 
for left ventricular systolic and diastolic function, respectively. In 
clinical studies, trimetazidine treatment leads to a substantial im-
provement in cardiac function and New York Heart Association 
function (NYHA) class in the heart failure population [65, 66]. The 
improvement of the left ventricular function is associated with a 
reduction of the inflammatory response in patients treated with 
trimetazidine [67]. Trimetazidine also improves the myocardial 
PCr/ATP ratio, suggesting that this agent preserves the intracellular 
levels of myocardial high energy phosphates [68].  
  CPT-1 inhibitors (such as etomoxir, perhexiline and oxfenicine) 
reduce mitochondrial FFA uptake. As a consequence, myocardial 
glucose substrate utilization increases [1, 10]. Studies with eto-
moxir demonstrated that chronic treatment with this agent results in 
improved sarcoplasmic Ca
2+ handling and increased SERCA2A 
expression, leading to improved cardiac function [69, 70]. Unfortu-
nately, this drug can produce serious adverse effects, including liver 
Fig. (3). A schematic representation of Akt-mediated feedback inhibition in heart failure.  
Insulin or IGF-1 signaling exerts cardioprotective effects through the acute activation of its down-stream effectors, such as IRS-1, PI3K and Akt. In contrast, 
the phosphorylation of IRS-1 induced by chronic Akt activation leads to their dissociation from PI3K, as well as proteasome-dependent degradation, thus 
leading to detrimental results. Similar negative feedback inhibition of IRS-1 is also observed in human heart failure where there is the persistent activation of 
Akt. Adapted from reference 45. 
DCM, dilated cardiomyopathy; GSK-3, glycogen synthase kinase-3; IGF-1, insulin like growth factor-1; IRS-1, insulin receptor substrate-1; PI3K, phosphoi-
nositide 3-kinase 
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toxicity. Another recent study has revealed the salutary effects of 
perhexiline in improving the myocardial oxygen consumption, left 
ventricular ejection fraction, symptoms, and exercise capacity in 
maximally treated heart failure patients [71].  
  There are three isoforms of PPARs: PPAR, PPAR, and 
PPAR , all of which are expressed in the heart. While PPAR and 
PPAR increase myocardial FAO rates, PPAR  agonists, such as, 
thiazolidines, actually decrease FAO rates by decreasing circulating 
FFA levels, and thus decreasing myocardial FFA uptake and oxida-
tion [72]. 
Catecholamines 
  Short-term stimulation of  -adrenergic receptors increases glu-
cose uptake, glycolysis and glucose oxidation. The activation of 
protein kinase A (PKA) and Ca
2+-calmodulin-dependent kinase 
(CaMK) by epinephrine, an adrenergic receptor agonist, leads to 
acute increases in PFK and Akt activity [73, 74]. Moreover, epi-
nephrine also increases mitochondrial Ca
2+ uptake, which activates 
PDH and other TCA cycle enzymes. In contrast, the long-term 
upregulation of catecholamines, often present in patients with heart 
failure, antagonizes the actions of insulin, promotes lipolysis, and 
increases circulating FFA levels, all of which can lead to insulin 
resistance [9]. This action is partly mediated through the negative 
feedback inhibition of either the insulin receptor [74] or of IRS-1 
[45]. Adrenergic blockade with carvedilol reduces FFA utilization 
in favor of greater glucose utilization in heart failure patients [75]. 
This change in myocardial energetics could provide a potential 
mechanism for the decreased myocardial oxygen consumption and 
improved energy efficiency seen with  -adrenergic receptor inhibi-
tors in the treatment of heart failure.  
RAAS
  Alterations in RAAS is centraly involved in the pathophysiol-
ogy of heart failure. We and others have previously reported that 
cardiac ACE activity and gene expression, as well as the local syn-
thesis of angiotensin II and aldosterone, are increased in the failing 
hearts [76-78]. The persistent activation of these RAAS compo-
nents contributes to altered insulin/IGF-1 signaling pathways and 
ROS formation, which induces endothelial dysfunction and insulin 
resistance [79]. There have been several reports demonstrating that 
persistent stimulation of aldosterone induces IRS-1 degradation, 
thus leading to insulin resistance [80, 81]. Moreover, increased 
aldosterone levels were shown to be associated with insulin resis-
tance in a heart failure population [82]. Therefore, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, and 
mineralocorticoid receptor inhibitors may all have favorable effects 
on the glucose metabolism and thereby restore insulin sensitivity 
[83, 84].  
CONCLUSION 
  The alterations in myocardial fuel selection and energetics play 
a key role in the pathogenesis and progression of heart failure. 
Shifting the energy metabolic pathways away from FFA utilization 
and toward glucose utilization can be an attractive novel therapeutic 
strategy for the prevention or early treatment of heart failure in 
terms of providing a more energy-efficient substrate usage. Mean-
while, special attention should be paid to insulin resistance, which 
is generally associated with advanced heart failure, and the devel-
opment of new therapies aimed at the improvement of insulin sensi-
tivity should be considered in order to take advantage of glucose as 
the preferred metabolic substrate in heart failure.  
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